RecruitingPhase 2NCT05436561

Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

A Multiple-center Phase II Study to Evaluate the Clinical Outcome of Reduced Conditioning Regimen With Melphalan, Busulfan and Fludarabine for Patients >=55 Years With Myeloid Malignancies.

Sponsor

Shanghai Jiao Tong University School of Medicine

Enrollment

61 participants

Start Date

Jun 1, 2022

Study Type

INTERVENTIONAL

Conditions

Disease Free Survival

Summary

In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.

Eligibility

Min Age: 55 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MBF-RIC for people with disease free survival. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 55 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMBF-RIC

Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan

Locations(2)

Blood & Marrow Transplantation Center, RuiJin Hospital

Shanghai, Shanghai Municipality, China

Shanghai No 6 Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05436561

Related Trials